Kevan Herold
Kevan Herold is an American endocrinologist who treats adult and child patients with type 1 and type 2 diabetes, diabetes that occurs after therapies for cancer, and hypoglycemia (low blood glucose levels). He graduated at Yale University.[1] He specializes in immunobiology.[2]
He is Professor of Immunobiology and of Medicine as well as Deputy Director, Yale Center for Clinical Investigation, Director of the Yale Diabetes Center and the TrialNet Center at Yale.[3] Recently, Dr. Herold was the principal investigator for a clinical trial that showed the effectiveness of teplizumab, a new drug that could delay type 1 diabetes development by two years. He is chair of NIDDK (National Institute of Diabetes and Digestive Diseases) TrialNet, an international network of type 1 diabetes researchers.
He was an author of a study that found that some beta cells survive the immune system's attack that end up with two populations of beta cells surviving because of a "duck and cove" strategy.[4]
References[edit]
- ↑ Richtel, Matt (2016-12-06). "An unleashed immune system can attack healthy organs as well as cancer". The Sydney Morning Herald. Retrieved 2018-10-01.
- ↑ UPI. "Study shows how some insulin-producing cells survive in diabetes - Breitbart". Breitbart. Retrieved 2018-10-01.
- ↑ "Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases". www.tmcnet.com. Retrieved 2018-10-01.
- ↑ "Yale study: Hope seen for producing insulin in type 1 diabetics". New Haven Register. 2017-02-11. Retrieved 2018-10-01.
 | This biographical article about a scientist is a stub. You can help EverybodyWiki by expanding it. |
This article "Kevan Herold" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Kevan Herold. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
